Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Active, not recruiting · Phase 2 · NCT06106295
Conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
At a glance
- Research payments reported, 2025
- $2.3M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Mayo Clinic
- Tested
- Metyrapone (drug)
- Dates
- Started 2023-12-19; completion 2028-02-01
- Results posted
- Not yet
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Esteve Pharmaceuticals LLC reported $2.3M in research payments for this study in 2025 (7 payments).
Products named: Metopirone
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic $2.3M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.